FDA approves Merck-Eisai Welireg-Lenvima combination for previously treated advanced kidney cancer on September 25, 2026 Advanced Renal Cell Carcinoma Approved belzutifan clear-cell RCC Eisai lenvatinib Lenvima LITESPARK-011 Merck United States Food and Drug Administration Welireg +